Industry

GENOA, Italy–(BUSINESS WIRE)–#autism–IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, and PsychoGenics Inc., a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that the companies have entered into a service … [Read more…]

Former Goldman Sachs Co-head of EMEA Healthcare Investment Banking, Partner and Managing Director brings extensive experience in corporate biotech and strategic finance SOMERVILLE, Mass.–(BUSINESS WIRE)–Generate Biomedicines, whose machine learning-powered generative biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced that Jason Silvers, M.D., … [Read more…]

Castle Biosciences surpasses 100,000 orders for its flagship risk-stratification test designed to help guide risk-appropriate treatment decisions for patients diagnosed with cutaneous melanoma FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a significant milestone for the Company’s DecisionDx®-Melanoma gene expression profile test, … [Read more…]

Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to demonstrate a survival benefit in this population Application being evaluated under FDA Real-Time Oncology Review and Project Orbis WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of ENHERTU® … [Read more…]

IRVING, Texas–(BUSINESS WIRE)–#teamvizient—Vizient, Inc., the nations’ largest member-driven health care performance improvement company, today announced a strategic partnership agreement with Mpirik, a cloud-based care pathway software company focused on cardiac care, that will enable physicians to make more informed decisions on patient care while helping to reduce undertreatment. The strategic partnership expands access to patient … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Anti-Thrombin III Testing Market 2022-2026” report has been added to ResearchAndMarkets.com’s offering. The anti-thrombin III testing market is poised to grow by $ 161.48 mn during 2022-2026, accelerating at a CAGR of 7.73% This study identifies the presence of various blood clotting disorders as one of the prime reasons driving the anti-thrombin … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Genetic Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The global genetic testing market reached a value of US$ 14.36 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 26.39 Billion by 2027, exhibiting a … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Disposable Syringes Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The global disposable syringes market reached a value of US$ 13.01 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 20.5 Billion by 2027, exhibiting a … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “US Health Equity Growth Opportunities” report has been added to ResearchAndMarkets.com’s offering. Health equity is achieved when all sections of the population have attained their full potential for health and well-being, regardless of cultural background or socioeconomic status. Inequities resulting from differences in health and overall living conditions need to be identified and … [Read more…]

Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU is the first HER2 directed therapy to demonstrate a survival benefit in this population Application being evaluated under FDA Real-Time Oncology Review and Project Orbis TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have received notification of acceptance by … [Read more…]